Plain-English translation of NCT05732831 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called for people with advanced cancers that have a specific genetic change (a missing piece of DNA called MTAP deletion). The study will test whether this medication is safe and how well it works, both on its own and when combined with another cancer drug called . Researchers will enroll about 225 people and monitor them at multiple hospitals across different countries.
Some cancers have a genetic mutation that makes them missing a particular gene (MTAP), and these tumors may be especially sensitive to a new type of cancer treatment. This trial exists to find out if this medication can help patients whose tumors have this specific genetic change, and whether combining it with existing immunotherapy might work even better.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth (as a pill) at doses that increase over time while researchers monitor your safety. You may receive the medication alone or combined with , depending on which study group you join. You will have regular visits to the hospital or clinic for blood tests, scans, and check-ins with your doctor. As long as the medication is working well and you are tolerating it, you can continue treatment until your cancer stops responding or side effects become too severe.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States